BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

Third Rock Ventures led a syndicate that invested $86 million in a series A round for MOMA Therapeutics, a newly launched start-up that will seek to interrogate a class of "molecular machines" that drive cellular...
BioCentury | May 24, 2018
Translation in Brief

Click chemistry HATRIC

Researchers at ETH Zurich have developed a click chemistry-based screening method that can identify all cell surface proteins that bind a ligand. The hope is that surface proteins exclusively present on select cell types will...
BioCentury | May 4, 2018
Clinical News

Cinclus' severe erosive GERD candidate well tolerated in Phase I

Cinclus Pharma AG (Basel, Switzerland) said single and multiple ascending doses of oral X842 for five days were well tolerated in an open-label, Swedish Phase I trial in about 39 healthy volunteers. The company is...
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
BioCentury | Apr 11, 2017
Distillery Therapeutics


INDICATION: Brain cancer Cell culture and mouse studies suggest Na+/K+ ATPase pump inhibitors could help treat glioma. In seven human glioma cell lines, the Na+/K+ ATPase pump inhibitor oleandrin decreased cell viability and migration compared...
BioCentury | Aug 22, 2016
Company News

Lee’s Pharmaceutical Holdings Ltd., ScinoPharm Taiwan deal

Lee’s Pharmaceutical’s CVie Therapeutics Ltd. subsidiary and ScinoPharm partnered to discover and develop “orally available” analogs of CVie’s istaroxime . Istaroxime, a luso-inotropic agent that inhibits Na+/K+ ATPase pump and activates ATPase Ca++ transporting cardiac muscle...
BioCentury | Nov 5, 2015
Distillery Therapeutics

Therapeutics: Na+/K+ ATPase pump; Src

Endocrine/metabolic disease INDICATION: Obesity In vitro and mouse studies suggest a peptide inhibitor of Src could help treat obesity. Previous studies identified a 20-amino acid peptide derived from the ATP binding domain of the Na+/K+...
BioCentury | Jun 29, 2015
Clinical News

RX108: Phase I started

Suzhou NeuPharma began an open-label, Australian Phase I trial of Rx10 8. Suzhou NeuPharma Co. Ltd. , Suzhou, China Product: Rx10 8 Business: Cancer Molecular target: Na+/K+ ATPase pump Description: Small molecule Na+/K+ ATPase pump inhibitor...
BioCentury | Jun 8, 2015
Clinical News

CJ-12420: Phase III started

CJ began a double-blind, Korean Phase III trial to compare 100 mg oral CJ-12420 once daily vs. 40 mg oral esomeprazole once daily for up to 8 weeks in about 280 patients. The trial start...
BioCentury | Jul 14, 2014
Clinical News

RQ-00000004: Phase I started

RaQualia began a Japanese Phase I trial of RQ-00000004. The product is in Phase II testing for GERD in Korea. CJ Group’s CJ CheilJedang Co. affiliate has exclusive rights to develop and commercialize RQ-00000004 in...
Items per page:
1 - 10 of 56